TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01884259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m² on day 1 of 21-days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m² on day 1 of 21-days cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m² on day 1 of 21-days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² on day 1 of 21-days cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 750 mg/m² day 1 to 5 during 24 hours of 21-days cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab Induction
Description: weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab Radioimmunotherapy
Description: weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab Radioimmunotherapy
Description: weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Boost irradiation
Description: First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost irradiation
Description: First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
Study: NCT00948363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kiwi fruits
Description: Daily intake of 3 kiwi fruits for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple
Description: Daily intake of 1 apple (equivalent in energy) for 8 weeks
Study: NCT02121600

Intervention type: OTHER
Group type: OTHER
Intervention: [F-18]-FCH
Description: Before the PET/MRI or PET/CT scan, patients will receive an \[F-18\]-Fluorocholine injection in the arm.

Intervention type: OTHER
Group type: OTHER
Intervention: [F-18]-FCH
Description: Before the PET/MRI or PET/CT scan, patients will receive an \[F-18\]-Fluorocholine injection in the arm.

Intervention type: RADIATION
Group type: OTHER
Intervention: PET scan
Description: A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment

Intervention type: RADIATION
Group type: OTHER
Intervention: PET scan
Description: A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI scan
Description: Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI scan
Description: Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment
Study: NCT04158076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe/Rosuvastatin
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET
Description: PO, Once daily(QD), 8weeks
Study: NCT02232373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low FODMAP dietary advice
Description: An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet. Second session after one month on re-introduction of FODMAP containing foods.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: low FODMAP dietary advice
Description: An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet. Second session after one month on re-introduction of FODMAP containing foods.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: Dietary supplementation with maltodextrin 5 grams twice daily for a month

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Oligofructose
Description: Dietary supplementation with oligofructose 5 grams twice daily for a month
Study: NCT02159703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TORS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiation Therapy
Study: NCT00579865

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
Study: NCT02330978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal transplantation of mesenchymal stem cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Culture and isolation of autologous bone-marrow mesenchymal stem cells
Study: NCT02116777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT03194386

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reassurance
Description: At the end of cares, before ED discharge, a trained psychologist will conduct a session in order to reassure patients about their future after ED visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye-Movement Desensitization and Reprocessing (EMDR)
Description: At the end of cares, before ED discharge, a trained psychologist will conduct a single EMDR session. Each session may last about 60 minutes
Study: NCT04968977

Intervention type: PROCEDURE
Intervention: PCI vs. CABG
Description: PCI vs. CABG
Study: NCT03683940

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Screening
Description: Subjects will undergo a low dose non contrast CT chest for lung cancer screening. The test will be performed by the UCH Radiology Department and read by board-certified chest radiologists using Lung-RADS criteria.
Study: NCT01027611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proparacaine HCL 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proparacaine HCL 0.5% + 4% lidocaine solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.5% viscous lidocaine gel
Study: NCT03200327

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: promontofixation
Description: reconstruction of cystoceles using a subvesical prosthesis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sacrospinofixation
Description: Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route
Study: NCT04116086

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Prostate Biopsy Test
Description: see earlier information
Study: NCT03820414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV 101
Description: (Different formulations)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV 101
Description: (Different formulations)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV 101
Description: (Different formulations)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV 101
Description: (Different formulations)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered IM in deltoid region of non-dominant arm
Study: NCT01329445

Intervention type: OTHER
Intervention: DeNovo NT, Natural Tissue Graft
Description: DeNovo NT Natural Tissue Graft of 1 or 2 lesions up to 5 cm squared in area.
Study: NCT01463670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
Study: NCT04670497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.5% with 1:200000 adrenaline
Description: regional anesthesia to block lumbar plexus for analgesia of lower limb

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.5% with 1:200000 adrenaline
Description: regional anesthesia to block lumbar plexus for analgesia of lower limb
Study: NCT03395548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol
Description: Used drug: Macrogol (osmotic laxative)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol
Description: Used drug: Macrogol (osmotic laxative)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol
Description: Used drug: Macrogol (osmotic laxative)
Study: NCT02554747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigated laser
Description: Aflibercept, Navilas®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laser
Description: Aflibercept, Pascal
Study: NCT02592551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI4736
Description: MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Tremelimumab Drug Product is formulated at a nominal concentration of 20 mg/mL in 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (weight/volume \[w/v\]) polysorbate 80, 0.27 mM disodium edetate dihydrate (EDTA), pH 5.5.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no other name
Description: Neither MEDI4736 nor Tremelimumab will be used.
Study: NCT00971165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: Oral losartan up to 100 mg daily fo 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone plus amiloride
Description: Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
Study: NCT04050670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Tirzepatide administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide administered SC
Study: NCT01355484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: subjects will be randomized to receive GTx-024 for the full duration of the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subject will receive placebo for the duration of the trial
Study: NCT02967081

Intervention type: PROCEDURE
Intervention: Collection of dentinal fluid using a cellulose membrane
Description: After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.

Intervention type: PROCEDURE
Intervention: Collection of dentinal fluid using a cellulose membrane
Description: After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.

Intervention type: PROCEDURE
Intervention: Collection of dentinal fluid using a cellulose membrane
Description: After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.

Intervention type: PROCEDURE
Intervention: Collection of dentinal fluid using a cellulose membrane
Description: After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.
Study: NCT01149889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively
Study: NCT01235559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses, once a day for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838] level 1
Description: Oral dose level 1, once a day for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838] level 2
Description: Oral dose level 2, once a day for 52 weeks
Study: NCT04163796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UPnRIDE power wheelchair
Description: The intervention will consist of approximately 3.5 hours per session, 3 times per week over 12 weeks. During each 3.5-hour session, subjects will be asked to stand at least 5 minutes during every 15 minutes or more as tolerated. One time each session, participants will be asked to perform the Activities of Daily Living course.
Study: NCT02950090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MobilWise
Description: see arm description for MobilWise above

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: see arm description for Fitbit above
Study: NCT03743311

Intervention type: PROCEDURE
Intervention: Hemorrhoidectomy, Thrombectomy , Operation on Longo method
Description: Surgical procedures for treatment of Hemorhoid

Intervention type: DRUG
Intervention: Detralex
Description: Conservative treatment of Hemorhoid

Intervention type: OTHER
Intervention: Combined therapy
Description: Surgical + conservative treatment of Hemorhoid
Study: NCT06320691

Intervention type: PROCEDURE
Intervention: Total Hip Arthroplasty
Description: Patients that underwent direct anterior approach total hip arthroplasty

Intervention type: PROCEDURE
Intervention: Total Hip Arthroplasty
Description: Patients that underwent direct anterior approach total hip arthroplasty

Intervention type: PROCEDURE
Intervention: General Anesthesia
Description: Patients that underwent general/systemic anesthesia before surgery

Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: Patients that underwent spinal/neuraxial anesthesia before surgery
Study: NCT00959036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 10 mg every 4 weeks until week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 10 mg every 8 weeks until week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 30 mg every 4 weeks until week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 80 mg every 4 weeks until week 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 80 mg every 8 weeks until week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Study: NCT03015675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: 20g/day, D1-3, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
Study: NCT00985803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity: Cardio training (CT)
Description: The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity: Endurance exercise training (ET)
Description: The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling.
Study: NCT02113085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-determination enhancement
Description: Self-determination enhancement through individual coaching and peer mentoring workshops
Study: NCT01112839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Group
Description: Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
Study: NCT01841411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
Study: NCT00625833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet once a day dosing for 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: Oral tablet once a day dosing for 10 weeks.
Study: NCT03223480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided gastrojejunstomy
Description: As listed in the arms description
Study: NCT02800408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain high-BCX maize
Description: The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined grain high-BCX maize
Description: The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whole grain white maize
Description: The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
Study: NCT02953639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basmisanil
Description: Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basmisanil
Description: Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
Study: NCT00906893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18F]-FMISO PET-CT
Description: pretherapy(\[18F\]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe \[18F\]-FMISO uptake will be used.